AEYE
AudioEye, Inc.
AEYE has the edge over ASTS overall, supported by lower modeled downside.
ASTS
AST SpaceMobile, Inc.
ASTS offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
AEYE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Strong | |
| Under pressure |
AEYE's cash flow is currently strong, and its revenue is stable, but its profitability and balance sheet are under pressure.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
AEYE PE Valuation
AEYE has no meaningful PE right now: it lost money over the past year.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
AEYE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for AEYE, with profitability improving.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
AEYE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.24 | — |
| Q3 2026 | -$0.25 | +$0.04 |
| Q2 2026 | -$0.37 | -$0.02 |
| Q1 2026 | -$0.30 | +$0.11 |
| Q4 2025 | -$0.25 | +$0.11 |
| Q3 2025 | -$0.29 | -$0.01 |
| Q2 2025 | -$0.35 | -$0.06 |
| Q1 2025 | -$0.41 | -$0.01 |
| Q4 2024 | -$0.36 | +$0.14 |
AEYE has the edge over ASTS on earnings, with more consistent year-over-year improvement.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
AEYE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11M | +7.2% |
| Q2 2026 | $10.7M | +8.7% |
| Q1 2026 | $10.6M | +8.4% |
| Q4 2025 | $10.5M | +7.9% |
| Q3 2025 | $10.2M | +15% |
| Q2 2025 | $9.9M | +16% |
| Q1 2025 | $9.7M | +20% |
| Q4 2024 | $9.7M | +24% |
AEYE's revenue has grown year over year every quarter since late 2020: $11M last quarter, up 7.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | +15 points |
| Q2 2026 | -5.6% | -8 points |
| Q1 2026 | -18% | -8.2 points |
| Q4 2025 | -7.8% | +5.3 points |
| Q3 2025 | -3.1% | +8 points |
| Q2 2025 | 2.5% | +8.3 points |
| Q1 2025 | -9.7% | -1.9 points |
| Q4 2024 | -13% | -6.8 points |
AEYE has the edge over ASTS on profitability, with a higher operating margin.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS's revenue has grown year over year for 11 quarters in a row: $42M last quarter, up 187% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
AEYE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.7M | +67% |
| Q2 2026 | $1M | -15% |
| Q1 2026 | $1.2M | +$1.3M |
| Q4 2025 | $2.5M | +377% |
| Q3 2025 | $1M | -32% |
| Q2 2025 | $1.2M | +205% |
| Q1 2025 | -$47K | -132% |
| Q4 2024 | $525K | -35% |
AEYE has the edge over ASTS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
AEYE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.7x | Elevated |
| Q2 2026 | 29.1x | High |
| Q1 2026 | 7.8x | High |
| Q4 2025 | 4.4x | High |
| Q3 2025 | 7.9x | High |
| Q2 2025 | 94.8x | High |
AEYE's net debt is about 3.7 years of its operating earnings (EBITDA), down from 7.9 years a year ago.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AEYE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.2 | Overbought |
| Stochastic | 84.2 | Overbought |
AEYE's weekly RSI is 74 (overbought) and its Stochastic is 84 (overbought).
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
AEYE PE vs Technology Sector
AEYE has no meaningful PE right now: it lost money over the past year.
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
AEYE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.39 | 52% above |
| 20 week MA | $7.90 | 81% above |
| 50 week MA | $7.89 | 81% above |
| 100 week MA | $10.6 | 35% above |
| 200 week MA | $11.0 | 30% above |
AEYE has the edge over ASTS on trend strength, trading above more of its moving averages.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has fallen below most of its moving averages, though it's still 2.8% above its 200-week average.
AEYE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.75 | $26.2 | +452% |
| 2021 | $26.2 | $7.00 | -73% |
| 2022 | $7.00 | $3.85 | -45% |
| 2023 | $3.85 | $5.42 | +41% |
| 2024 | $5.42 | $16.1 | +197% |
| 2025 | $16.1 | $10.7 | -34% |
| 2026 YTD | $10.7 | $14.3 | +34% |
AEYE has the edge over ASTS on returns for 2026, with the stronger performance.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.